RU94040386A - Синтетический пептид, синтетический липопептид, иммуногенный коньюгат, вектор, диагностический реагент, метод определения инфекций, антитета, способ получения олигомера, синтетическая вакцина против haemophilus influenzae, защищенный полисахарид - Google Patents
Синтетический пептид, синтетический липопептид, иммуногенный коньюгат, вектор, диагностический реагент, метод определения инфекций, антитета, способ получения олигомера, синтетическая вакцина против haemophilus influenzae, защищенный полисахаридInfo
- Publication number
- RU94040386A RU94040386A RU94040386/13A RU94040386A RU94040386A RU 94040386 A RU94040386 A RU 94040386A RU 94040386/13 A RU94040386/13 A RU 94040386/13A RU 94040386 A RU94040386 A RU 94040386A RU 94040386 A RU94040386 A RU 94040386A
- Authority
- RU
- Russia
- Prior art keywords
- synthetic
- haemophilus influenzae
- vaccine against
- antibodies
- vector
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 4
- 241000606768 Haemophilus influenzae Species 0.000 title claims abstract 3
- 229940047650 haemophilus influenzae Drugs 0.000 title claims abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 108010028921 Lipopeptides Proteins 0.000 title 1
- 238000003556 assay Methods 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000003153 chemical reaction reagent Substances 0.000 title 1
- 150000004676 glycans Chemical class 0.000 title 1
- 230000002163 immunogen Effects 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 229920001282 polysaccharide Polymers 0.000 title 1
- 239000005017 polysaccharide Substances 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 229940126577 synthetic vaccine Drugs 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract 3
- 102000004169 proteins and genes Human genes 0.000 claims abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 230000000890 antigenic effect Effects 0.000 claims abstract 2
- 229960005486 vaccine Drugs 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 238000010647 peptide synthesis reaction Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/08—Polyoxyalkylene derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/851—Haemophilus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Синтетический пептид имеет аминокислотную последовательность, относящуюся по крайней мере к одной антигенной детерминанте по крайней мере одного белка, обычно структурного, в особенности Р1, Р2 и Р6 -белкам Haemophilus influenzae (Нi ), в частности типа В, и используется в виде химерной липофильной Т-В-формы, привязанной к молекуле носителя, например синтетической PRP-молекуле, и/или полимеризованного и образующего молекулярные агрегаты, как вакцина против Hi.
Claims (1)
- Синтетический пептид имеет аминокислотную последовательность, относящуюся по крайней мере к одной антигенной детерминанте по крайней мере одного белка, обычно структурного, в особенности Р1, Р2 и Р6 -белкам Haemophilus influenzae (Нi ), в частности типа В, и используется в виде химерной липофильной Т-В-формы, привязанной к молекуле носителя, например синтетической PRP-молекуле, и/или полимеризованного и образующего молекулярные агрегаты, как вакцина против Hi.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929202219A GB9202219D0 (en) | 1992-02-03 | 1992-02-03 | A synthetic heamophilus influenzae conjugate vaccine |
GB9202219.3 | 1992-02-03 | ||
PCT/CA1993/000041 WO1993015205A2 (en) | 1992-02-03 | 1993-02-03 | Synthetic haemophilus influenzae conjugate vaccine |
Publications (2)
Publication Number | Publication Date |
---|---|
RU94040386A true RU94040386A (ru) | 1996-05-10 |
RU2141527C1 RU2141527C1 (ru) | 1999-11-20 |
Family
ID=10709711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU94040386A RU2141527C1 (ru) | 1992-02-03 | 1993-02-03 | Синтетический пептид, синтетический липопептид, иммуногенный конъюгат (варианты), способ получения олигомера, защищенный твердым монометиловым эфиром полиэтиленгликоля полисахарид |
Country Status (11)
Country | Link |
---|---|
US (3) | US6018019A (ru) |
EP (1) | EP0625203A1 (ru) |
JP (4) | JP3421337B2 (ru) |
KR (1) | KR100246122B1 (ru) |
AU (1) | AU669354B2 (ru) |
CA (1) | CA2129101C (ru) |
FI (1) | FI943591A (ru) |
GB (1) | GB9202219D0 (ru) |
NO (1) | NO942867L (ru) |
RU (1) | RU2141527C1 (ru) |
WO (1) | WO1993015205A2 (ru) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2551778C2 (ru) * | 2009-03-30 | 2015-05-27 | Дайити Санкио Компани, Лимитед | Способ индукции гибели плюрипотентных стволовых клеток и дифференцированных клеток, отличных от кардиомиоцитов |
RU2583579C2 (ru) * | 2009-02-02 | 2016-05-10 | Валио Лтд | Новые пептиды и способы их получения |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8924473D0 (en) * | 1989-10-31 | 1989-12-20 | Connaught Lab | Outer membrane protein p1 and peptides of haemophilus influenzae b |
GB9202219D0 (en) * | 1992-02-03 | 1992-03-18 | Connaught Lab | A synthetic heamophilus influenzae conjugate vaccine |
US6242578B1 (en) | 1994-02-17 | 2001-06-05 | Samuel Bogoch | Aglyco products and methods of use |
US5532405A (en) * | 1994-04-29 | 1996-07-02 | Exxon Chemical Patents Inc. | Preparation of plasticizer or polyol esters by the staged addition of the lower boiling point reactant |
GB9422096D0 (en) * | 1994-11-02 | 1994-12-21 | Biocine Spa | Combined meningitis vaccine |
US5681570A (en) * | 1995-01-12 | 1997-10-28 | Connaught Laboratories Limited | Immunogenic conjugate molecules |
KR19990007858A (ko) * | 1995-04-17 | 1999-01-25 | 존 더블유.로우 | 박테리아의 리포프로테인으로 폴리사카라이드에 대한 면역반응의 유도및 강화 |
FR2734484B1 (fr) * | 1995-05-24 | 1997-06-27 | Pasteur Merieux Serums Vacc | Composition vaccinale liquide et procede de fabrication |
US20030157129A1 (en) * | 1995-06-23 | 2003-08-21 | Smithkline Beecham Biologicals S.A. | Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein |
US6761892B1 (en) * | 1995-08-18 | 2004-07-13 | Sloan-Kettering Institute For Cancer Research | Heat shock protein-based vaccines and immunotherapies |
US6267961B1 (en) * | 1996-11-22 | 2001-07-31 | Baxter International Inc. | Direct methods for molar-mass determination of fragments of Haemophilus influenzae type b capsular polysaccharides and vaccine preparation |
US6299881B1 (en) * | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
ATE328611T1 (de) * | 1997-03-27 | 2006-06-15 | Pasteur Institut | Multiple,kohlenhydrathaltige glycopeptid-antigene,daraus entwickelte impfstoffe sowie deren verwendung |
US6676946B2 (en) * | 1997-03-27 | 2004-01-13 | Institut Pasteur | Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof |
US20070237785A1 (en) * | 1997-03-27 | 2007-10-11 | Institut Pasteur | Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof |
US5972339A (en) * | 1997-11-13 | 1999-10-26 | The General Hospital Corporation | Method of eliciting anti-HIV-1 helper T cell responses |
NZ505161A (en) * | 1997-11-18 | 2003-07-25 | Univ South Carolina | Synthetic linear amino acid constructs which support epitopes of antigens |
US6572867B1 (en) * | 1998-04-15 | 2003-06-03 | Baxter International Inc. | Inhibition of xenoreactive antibodies |
AU776618B2 (en) * | 1998-12-19 | 2004-09-16 | Ml Laboratories Plc | Improvement of tolerance to a xenograft |
US7384640B1 (en) * | 1999-09-30 | 2008-06-10 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant |
DE60139243D1 (de) * | 2000-03-01 | 2009-08-27 | Binax Inc | Methode zum nachweis von (ziel)bakterien oder kohlenhydrat-antigenen dieser (ziel)bakterien |
US7556807B2 (en) | 2001-02-20 | 2009-07-07 | Kane Biotech, Inc. | Signal peptides, nucleic acid molecules and methods for treatment of caries |
US7597895B2 (en) * | 2001-02-20 | 2009-10-06 | The Governing Council Of The University Of Toronto | Signal peptides, nucleic acid molecules and methods for treatment of caries |
US7442761B2 (en) | 2003-06-06 | 2008-10-28 | Samuel Bogoch | Replikin peptides and uses thereof |
KR100906102B1 (ko) * | 2001-03-27 | 2009-07-07 | 사무엘 보고치 | 레플리킨 펩타이드 및 그의 이용 |
US7774144B2 (en) * | 2001-10-26 | 2010-08-10 | Samuel Bogoch | System and method for identifying complex patterns of amino acids |
US7452963B2 (en) * | 2001-03-27 | 2008-11-18 | Samuel Bogoch | Replikin peptides and antibodies therefore |
US7189800B2 (en) * | 2001-03-27 | 2007-03-13 | Samuel Bogoch | Replikin peptides in rapid replication of glioma cells and in influenza epidemics |
US7420028B2 (en) * | 2001-03-27 | 2008-09-02 | Samuel Bogoch | Replikins and methods of identifying replikin-containing sequences |
US7894999B2 (en) | 2001-03-27 | 2011-02-22 | Samuel Bogoch | Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds |
US20040043419A1 (en) * | 2001-04-17 | 2004-03-04 | Rothman James E. | Javelinization of protein antigens to heat shock proteins |
EP1404279A4 (en) * | 2001-06-07 | 2007-08-08 | Wyeth Corp | MUTANT FORMS OF CHOLERA HOLOTOXIN AS ADJUVANT |
KR100898648B1 (ko) * | 2001-06-07 | 2009-05-22 | 와이어쓰 홀딩스 코포레이션 | 보조제로서 콜레라 홀로톡신의 돌연변이체 형태 |
CN1688605B (zh) | 2002-08-12 | 2011-01-12 | 昆士兰医学研究所理事会 | 包含辅助t细胞和细胞毒性t淋巴细胞(ctl)表位的新免疫原性脂肽 |
US7569225B2 (en) | 2002-08-12 | 2009-08-04 | The Council Of The Queensland Institute Of Medical Research | Immunogenic lipopeptides comprising T-helper and B-cell epitopes |
US7420037B2 (en) * | 2003-02-13 | 2008-09-02 | Antigenics Inc. | Heat shock protein-based vaccines and immunotherapies |
US7309491B2 (en) * | 2003-04-11 | 2007-12-18 | Antigenics Inc. | Heat shock protein-based vaccines and immunotherapies |
MXPA05010881A (es) * | 2003-04-11 | 2006-05-31 | Antigenics Inc | Vacunas e inmunoterapias a base de proteina de choque termico mejorada. |
US8494781B2 (en) * | 2003-06-06 | 2013-07-23 | Samuel Bogoch | Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds |
US9254315B2 (en) | 2004-04-28 | 2016-02-09 | Samuel Bogoch | Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds |
EP2092059A4 (en) * | 2006-10-24 | 2012-03-28 | Bogoch Samuel | METHOD FOR FORECASTING INFLUENZA EXCESSIONS BY CORRELATION OF AN INCREASED REPLICINE MIRROR IN WHITE SPOT AND / OR TAURA VIRUSES IN CRABES |
CA2676028A1 (en) * | 2007-01-18 | 2008-11-27 | Samuel Bogoch | Methods of determining lethality of pathogens and malignancies involving replikin peak genes |
MX2009013091A (es) * | 2007-05-30 | 2010-07-30 | Bogoch Samuel | Peptidos de repliquina sinteticos contra infeccion patogenica de invertebrados en acuicultura. |
US20090269367A1 (en) * | 2008-04-23 | 2009-10-29 | Samuel Bogoch | Methods and compounds for mitigating pathogenic outbreaks using replikin count cycles |
US20100144589A1 (en) * | 2008-08-08 | 2010-06-10 | Samuel Bogoch | Methods of predicting cancer lethality using replikin counts |
KR20110111381A (ko) * | 2009-01-07 | 2011-10-11 | 오츠카 세이야쿠 가부시키가이샤 | 전 인플루엔자균의 측정방법 |
US9233148B2 (en) | 2009-01-09 | 2016-01-12 | Samuel Bogoch | Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza |
JP6091214B2 (ja) * | 2009-11-16 | 2017-03-08 | ザ ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン,インコーポレイティド | ポリ−グリセロールリン酸をベースにした抗グラム陽性細菌ワクチン |
WO2012170356A1 (en) | 2011-06-04 | 2012-12-13 | Rochester General Hospital Research Institute | Compositions and methods related to p6 of haemophilus influenzae |
EP2968423A4 (en) * | 2013-03-15 | 2016-11-09 | Univ Arkansas | COMPOSITIONS AND METHODS FOR INCREASING IMMUNE REACTIONS AGAINST ENTERAL PATHOGENES |
EP3077410B1 (en) * | 2013-12-03 | 2021-02-03 | Virometix AG | Proline-rich peptides protective against s. pneumoniae |
CN105585633B (zh) * | 2016-03-08 | 2019-06-21 | 湖北工业大学 | 抗人流感嗜血杆菌p6蛋白抗体及应用该抗体的免疫层析试剂盒 |
EP3717632B1 (en) | 2017-11-30 | 2022-10-26 | F. Hoffmann-La Roche AG | B-cell cultivation method |
US11530432B2 (en) | 2018-03-19 | 2022-12-20 | Northwestern University | Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates |
JP2023542141A (ja) * | 2020-09-15 | 2023-10-05 | ザ ユニバーシティー オブ モンタナ | 繊維状バクテリオファージを標的化する組成物および方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8610983D0 (en) * | 1986-05-06 | 1986-06-11 | Connaught Lab | Enhancement of antigen immunogenicity |
JP2534529B2 (ja) * | 1986-07-24 | 1996-09-18 | ブリティシュ・テレコミュニケ−ションズ・パブリック・リミテッド・カンパニ | 放射発生器 |
US5173294A (en) * | 1986-11-18 | 1992-12-22 | Research Foundation Of State University Of New York | Dna probe for the identification of haemophilus influenzae |
NZ223009A (en) * | 1986-12-31 | 1990-06-26 | Nl Rivm Of Thoven | Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens |
AU623353B2 (en) * | 1987-12-10 | 1992-05-14 | Board Of Regents, The University Of Texas System | Methods and compositions for the production of haemophilus influenzae type b major outer membrane protein antigens |
EP0320942A3 (en) * | 1987-12-18 | 1989-10-04 | American Cyanamid Company | Novel polysaccharides novel macromolecular conjugates of the polysaccharides |
CA1340888C (en) * | 1988-09-01 | 2000-02-01 | Algis Anilionis | Vaccines and diagnostic assays for haemophilus influenzae |
CA2006587C (en) * | 1988-12-23 | 2000-01-18 | Robert W. Tolan | Membrane proteins and peptides of haemophilus influenzae type b |
ES2081864T3 (es) * | 1989-03-29 | 1996-03-16 | Univ New York State Res Found | Metodo para purificar una proteina de la membrana exterior de haemophilus influenzae. |
WO1990011778A1 (en) * | 1989-04-12 | 1990-10-18 | The Rockefeller University | Dendritic polymer of multiple antigen peptide system useful as anti-malarial vaccine |
GB8924473D0 (en) * | 1989-10-31 | 1989-12-20 | Connaught Lab | Outer membrane protein p1 and peptides of haemophilus influenzae b |
GB9202219D0 (en) * | 1992-02-03 | 1992-03-18 | Connaught Lab | A synthetic heamophilus influenzae conjugate vaccine |
US6153406A (en) * | 1993-07-23 | 2000-11-28 | North American Vaccine, Inc. | Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B |
-
1992
- 1992-02-03 GB GB929202219A patent/GB9202219D0/en active Pending
-
1993
- 1993-02-03 EP EP93903129A patent/EP0625203A1/en not_active Withdrawn
- 1993-02-03 JP JP51282493A patent/JP3421337B2/ja not_active Expired - Fee Related
- 1993-02-03 CA CA002129101A patent/CA2129101C/en not_active Expired - Fee Related
- 1993-02-03 US US08/256,839 patent/US6018019A/en not_active Expired - Fee Related
- 1993-02-03 AU AU34469/93A patent/AU669354B2/en not_active Ceased
- 1993-02-03 WO PCT/CA1993/000041 patent/WO1993015205A2/en active Application Filing
- 1993-02-03 RU RU94040386A patent/RU2141527C1/ru not_active IP Right Cessation
- 1993-02-03 KR KR1019940702655A patent/KR100246122B1/ko not_active IP Right Cessation
-
1994
- 1994-08-02 NO NO942867A patent/NO942867L/no not_active Application Discontinuation
- 1994-08-02 FI FI943591A patent/FI943591A/fi not_active Application Discontinuation
-
1995
- 1995-06-07 US US08/475,989 patent/US5679352A/en not_active Expired - Fee Related
- 1995-06-07 US US08/475,985 patent/US5972349A/en not_active Expired - Fee Related
-
1998
- 1998-10-21 JP JP10336442A patent/JPH11269188A/ja not_active Withdrawn
-
2000
- 2000-05-29 JP JP2000197292A patent/JP2001064201A/ja not_active Withdrawn
-
2006
- 2006-01-12 JP JP2006005426A patent/JP2006131642A/ja not_active Withdrawn
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2583579C2 (ru) * | 2009-02-02 | 2016-05-10 | Валио Лтд | Новые пептиды и способы их получения |
RU2551778C2 (ru) * | 2009-03-30 | 2015-05-27 | Дайити Санкио Компани, Лимитед | Способ индукции гибели плюрипотентных стволовых клеток и дифференцированных клеток, отличных от кардиомиоцитов |
Also Published As
Publication number | Publication date |
---|---|
CA2129101C (en) | 2004-08-10 |
US5972349A (en) | 1999-10-26 |
FI943591A (fi) | 1994-09-28 |
AU669354B2 (en) | 1996-06-06 |
EP0625203A1 (en) | 1994-11-23 |
JPH07505522A (ja) | 1995-06-22 |
JPH11269188A (ja) | 1999-10-05 |
JP2001064201A (ja) | 2001-03-13 |
CA2129101A1 (en) | 1993-08-05 |
GB9202219D0 (en) | 1992-03-18 |
KR100246122B1 (ko) | 2000-03-15 |
JP3421337B2 (ja) | 2003-06-30 |
US5679352A (en) | 1997-10-21 |
WO1993015205A2 (en) | 1993-08-05 |
AU3446993A (en) | 1993-09-01 |
FI943591A0 (fi) | 1994-08-02 |
NO942867L (no) | 1994-10-03 |
WO1993015205A3 (en) | 1994-03-03 |
KR950700416A (ko) | 1995-01-16 |
US6018019A (en) | 2000-01-25 |
NO942867D0 (ru) | 1994-08-02 |
JP2006131642A (ja) | 2006-05-25 |
RU2141527C1 (ru) | 1999-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU94040386A (ru) | Синтетический пептид, синтетический липопептид, иммуногенный коньюгат, вектор, диагностический реагент, метод определения инфекций, антитета, способ получения олигомера, синтетическая вакцина против haemophilus influenzae, защищенный полисахарид | |
Mühlradt et al. | Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration | |
Braun | Covalent lipoprotein from the outer membrane of Escherichia coli | |
Toyoshima et al. | Myosin subfragment-1 is sufficient to move actin filaments in vitro | |
IE832394L (en) | Immunogenic protein or peptide complex vaccine. | |
DE3588203D1 (de) | Durch pre-S-Gen kodierte Hepatitis-B-Peptid-Immunogene, Vakzine, Diagnostika und synthetische Lipid-Bläschenträger | |
RU94045919A (ru) | Антитела, клетки, полипептид, днк векторы, способ получения полипептида, способ получения антитела, фармацевтическая композиция | |
CA2338989A1 (en) | Antibodies for detecting microorganisms | |
WO2013065009A1 (en) | A sortase-click reaction suite for synthesis of multivalent dendrimeric protein assembly | |
GR3032150T3 (en) | Synthetic antigens for the detection of antibodies to hepatitis C virus | |
Strong et al. | Isolation, characterization and synthesis of peptides from human fibrinogen that block the staphylococcal clumping reaction and construction of a synthetic clumping particle | |
CA2217522A1 (en) | Isolated frpb nucleic acid molecule and vaccine | |
Glass | Enzymes as reagents in the synthesis of peptides | |
WO1991008220A1 (en) | A method for the stepwise, controlled synthesis of chemical species, particularly peptides, coupled products obtained by the method and the use of these coupled products, e.g. as vaccines | |
Lecadet et al. | Analysis of a protein fraction in the spore coats of Bacillus thuringiensis: comparison with crystal protein | |
KR100366482B1 (ko) | 백신으로서 정제된 분류가능하지 않은 헤모필루스 인프루엔자 p5단백질, 및 그의 정제방법 | |
CA2128407A1 (en) | Synthetic peptides for a rubella vaccine | |
CA1337283C (en) | Method for the selective cleavage of fusion proteins | |
US5258504A (en) | Process for the purification of streptolysin O, intact streptolysin O obtainable by this process | |
FR2694938B1 (fr) | Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant. | |
Deal et al. | Solubilization, isolation, and immunochemical characterization of the major outer membrane protein from Rhodopseudomonas sphaeroides. | |
AU6393990A (en) | Hiv related peptides | |
WO1995000540A1 (en) | Synthetic carrier and immunogen | |
SE9402490D0 (sv) | Vitronection binding protein | |
Tadros et al. | The localization of pigment-binding polypeptides in membranes of Rhodopseudomonas viridis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20090204 |